Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXCR2-transduced TILs in Metastatic Melanoma
NCT01740557Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2015
- Primary completion
- Apr 2023
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of cxcr2-transduced autologous tumor-infiltrating lymphocytes in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2015; status: completed.
02
Drugs
cxcr2-transduced autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01740557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01740557.